Доступ предоставлен для: Guest
Critical Reviews™ in Eukaryotic Gene Expression

Выходит 6 номеров в год

ISSN Печать: 1045-4403

ISSN Онлайн: 2162-6502

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 1.6 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.2 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.3 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00058 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.33 SJR: 0.345 SNIP: 0.46 CiteScore™:: 2.5 H-Index: 67

Indexed in

Options for the Treatment of Benign Prostatic Hyperplasia

Том 22, Выпуск 4, 2012, pp. 281-287
DOI: 10.1615/CritRevEukarGeneExpr.v22.i4.20
Get accessGet access

Краткое описание

Purpose: Benign prostatic hyperplasia (BPH) is uncontrolled human prostatic epithelial and stromal cell proliferation and delayed cell death, resulting in clinical lower urinary tract symptoms (LUTS) and possibly urine retention for the majority of men as they age.
Materials and Methods: The medical literature was searched and analyzed to present the current medical and surgical therapies for men with BPH and LUTS.
Results: Active surveillance and medical therapies have advanced rapidly over the past twenty years, with the majority of men with symptomatic BPH and LUTS responding well to these therapies. Surgical therapies, once the mainstay of therapy for men with symptomatic BPH and LUTS, have become selective minimally invasive procedures designed for specific prostate gland anatomical configurations and medical refractive clinical situations.
Conclusion: Men with symptomatic BPH and LUTS today are treated successfully with active surveillance and medical and surgical therapy. Exciting new insights into the biology of benign and cancerous prostate cellular proliferation, and their response to therapy, offer new research possibilities.

Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции Цены и условия подписки Begell House Контакты Language English 中文 Русский Português German French Spain